ArticleTherapeutic advances in neurological disorders2021
Disease-modifying therapy prescription patterns in people with multiple sclerosis by age.
Article in Therapeutic advances in neurological disorders, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.
- Adverse effects of immunotherapies for multiple sclerosis: a network meta-analysis.The Cochrane database of systematic reviews · 2023Pooled it
- Cross sectional analyses indicated that body fat distribution was not associated with performance-based and self-reported outcomes among ambulatory people with multiple sclerosis.Multiple sclerosis and related disorders · 2026Article
- Targeting senescent microglia in progressive multiple sclerosis: a geroscience-informed approach.Frontiers in immunology · 2025Article
- Real-world use of disease-modifying therapy in persons with multiple sclerosis aged 55 and over.BMJ neurology open · 2025Article
- Patient Experiences with the Impacts of Multiple Sclerosis & Disease-Modifying Therapies.ClinicoEconomics and outcomes research : CEOR · 2025Article
- Reasons for Hospital Admission in Individuals With Multiple Sclerosis.International journal of MS care · 2024Article
- De-escalation and Discontinuation of Disease-Modifying Therapies in Multiple Sclerosis.Current neurology and neuroscience reports · 2024Review
- Treatment Satisfaction with Teriflunomide in Patients with Multiple Sclerosis: A Systematic Review of Observational Studies.Medical journal of the Islamic Republic of Iran · 2024Review
- Treatment Patterns by Race and Ethnicity in Newly Diagnosed Persons with Multiple Sclerosis.Drugs - real world outcomes · 2023Article
- Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes.Multiple sclerosis and related disorders · 2022Article
- Trends in the use of disease-modifying therapies among reproductive-aged women with multiple sclerosis in the United States from 2010 to 2019.Pharmacoepidemiology and drug safety · 2022Article
- Multiple Sclerosis: Systemic Challenges to Cost-Effective Care.American health & drug benefits · 2022Review
- Evolution of Disease Modifying Therapy Benefits and Risks: An Argument for De-escalation as a Treatment Paradigm for Patients With Multiple Sclerosis.Frontiers in neurology · 2021Article
- Disease-Modifying Drug Uptake and Health Service Use in the Ageing MS Population.Frontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDisease-modifying therapies (DMTs) for multiple sclerosis (MS) are approved for their ability to reduce disease activity, namely clinical relapses and signal changes on magnetic resonance imaging (MRI). Disease activity appears age dependent. Thus, the greatest benefit would be expected in younger people with MS (PwMS) whereas benefits in the elderly are uncertain.
methodsReal-world data were obtained from PwMS from the North American Research Committee on Multiple Sclerosis (NARCOMS) registry and the US Department of Veterans Affairs Multiple Sclerosis Surveillance Registry (MSSR).
results6948 PwMS were surveyed from NARCOMS, and the MSSR had 1719 participants. In younger adult PwMS 40-years old or less, 183 (61.4%) in NARCOMS and 179 (70.5%) in the MSSR were prescribed DMTs. Among PwMS over age 60, 1575 (40.1%) in NARCOMS and 239 (36.3%) in the MSSR were prescribed DMTs. More PwMS in the age group of 31-40 (
conclusionThese findings suggest that DMTs are under-utilized in the younger population and continue to be commonly prescribed in the elderly. Broader access may explain the higher prescription rate of DMTs in US veterans.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.